

Pembrolizumab KEYNOTE-017

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects




Other adjustments



Pembrolizumab KEYNOTE-017

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers
 Therapeutic Indication: Adult and pediatric patients with recurrent, locally advanced or metastatic Merkel cell carcinoma
 Experimental Arm: Pembrolizumab
 Control Arm: Single arm

